Molgramostim
Highest phase reached
Phase 3
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Protein
- Drug name
- Molgramostim
- leucomax
- Leucomax
- g scf granulocyte colony stimulating factor
- G-SCF (Granulocyte-colony stimulating factor)
- GMCSF (granulocyte macrophage colony stimulating factor)
- granulocyte macrophage colony stimulating factor
- Granulocyte Macrophage Colony Stimulating Factor
- granulocyte macrophage colony stimulating factor molgramostim
- granulocyte macrophage colony stimulating factor molgramostim mi
- Granulocyte Macrophage-colony Stimulating Factor
- GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR
- Granulocyte-macrophage colony stimulating factor
- Granulocyte-macrophage colony-stimulating factor
- Granulocyte-macrophage Colony-stimulating Factor
- Granulocyte-Macrophage Colony-Stimulating Factor
- Granulocyte-macrophage colony-stimulating factor molgramostim
- GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR MOLGRAMOSTIM [MI]
- Granulocyte-macrophage colony-stimulating factor subcutaneous injection
- Leucomax
- molgradex
- Molgradex
- molgramostim
- Molgramostim
- Molgramostim (genetical recombination)
- MOLGRAMOSTIM (GENETICAL RECOMBINATION) [JAN]
- molgramostim [INN]
- MOLGRAMOSTIM [JAN]
And 18 more, listed on the interactive page.
- ATC classification codes
- L03AA03
Sources for recorded values
- CAS registry numbers
- 99283-10-0
- ChEMBL ID
- CHEMBL2109134
- RxNorm IDs (RxCUI)
- 70161
- FDA ingredient codes (UNII)
- B321AL142J
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -stim; -stim
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Mycobacterium Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009429
- Subject identifier
- D009164
- Condition
- Ascites
- Highest recorded phase
- 1
- Condition identifier
- HP:0001541
- Subject identifier
- D001201
- Condition
- Pulmonary Alveolar Proteinosis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0012579
- Subject identifier
- D011649
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000180
- Condition identifier
- EFO_0000222
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000389
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000694
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007456
- Highest recorded phase
- 1
- Condition identifier
- EFO_0009429
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000211
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001904
- Highest recorded phase
- 2
- Condition identifier
- GO_0042060
- Highest recorded phase
- 1
- Condition identifier
- HP_0000789
- Condition identifier
- HP_0001541
- Highest recorded phase
- 1
- Condition identifier
- HP_0100806
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001437
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004948
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004967
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004986
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005008
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005012
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005015
- Condition identifier
- MONDO_0005023
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005059
- Highest recorded phase
- 2
And 57 more, listed on the interactive page.
- Event
- bone marrow failure
- Reports
- 9
- Reporting signal score
- 28.6889
- Event
- capillary leak syndrome
- Reports
- 5
- Reporting signal score
- 25.3628
- Event
- febrile neutropenia
- Reports
- 4
- Reporting signal score
- 5.94899
- Event
- frostbite
- Reports
- 1
- Reporting signal score
- 5.85232
- Event
- karyotype analysis abnormal
- Reports
- 1
- Reporting signal score
- 6.34931
- Event
- low birth weight baby
- Reports
- 3
- Reporting signal score
- 9.36628
- Event
- mutagenic effect
- Reports
- 1
- Reporting signal score
- 7.85289
- Event
- pupillary reflex impaired
- Reports
- 2
- Reporting signal score
- 8.39556
- Event
- sjogren's syndrome
- Reports
- 2
- Reporting signal score
- 6.90496
- NCT00880243
- NCT01729663
- NCT02595060
- NCT02702180
- NCT03482752
- NCT04544293
- NCT06431776
- NCT03421743
- NCT04569877
- NCT05501340
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (143)
- A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
- A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
- A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis
- A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)
- A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B
- A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.
- A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation
- A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
- A Study of ARRY-520 in Patients With Advanced Cancer
- A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
- A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma
- A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
- A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
- A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)
- A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides
- Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
- Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma
- An Evaluation of the Spectra Optia CMNC Collection Procedure
Approved for (1)
- Neoplasm
In development for (6)
- Acute myeloid leukemia Phase 3
- Autoimmune pulmonary alveolar proteinosis Phase 3
- COVID-19 Phase 2
- Cutaneous melanoma Phase 2
- Mycobacterial infectious disease Phase 2
- Severe acute respiratory syndrome Phase 2